New York, Jan 12, 2026, 14:44 ET — Regular session underway
Nuvation Bio Inc shares tumbled almost 18% on Monday following news of a licensing deal with Japan’s Eisai and initial sales data for its lung-cancer treatment. The stock slipped 17.7% to $6.62, after fluctuating between $8.34 and $6.32 on roughly 11.4 million shares traded.
This is crucial now as Nuvation aims to show it’s more than just a development-stage player and can operate as a commercial drugmaker. The market has little patience for any slip in early prescription numbers, even with plenty of cash on hand.
The Eisai deal also changes the nature of the gamble. It aims to extend taletrectinib’s reach beyond the U.S. but keeps the American launch under the company’s own control. For investors, it offers new clues on timing and financing just as the industry converges for J.P. Morgan week.
Nuvation handed Eisai exclusive rights to develop and commercialize taletrectinib across Europe and many regions outside the U.S., China, and Japan, while retaining U.S. commercial rights. Eisai will shell out €50 million upfront, plus up to €145 million tied to regulatory and commercial milestones, along with tiered royalties that could climb into the high teens, the companies said. A European marketing authorization application—essentially the approval dossier—is set for submission in the first half of 2026. Hung described the deal as a “major global expansion milestone,” and Eisai’s Terushige Iike added the drug “has the potential to become a standard of care” in the EU. SEC
H.C. Wainwright cut its price target on Nuvation to $17 from $18 but maintained a Buy rating, TheFly reported. The firm noted that fourth-quarter Ibtrozi sales came in “inline with estimates.” TipRanks
IBTROZI, a once-daily pill, has been approved in the U.S. for treating ROS1-positive non-small cell lung cancer, a subtype marked by alterations in the ROS1 gene. Competitors on the market include Bristol-Myers Squibb’s Augtyro, Pfizer’s Xalkori, and Roche’s Rozlytrek.
On Monday, Nuvation updated its investor deck, projecting a pro forma cash balance near $589 million, which includes about $60 million from Eisai’s upfront payment. The company also highlighted an extra $50 million term loan accessible until June 30, 2026, and indicated this cash reserve should fund a route to profitability without needing more capital.
The stock’s move implies investors are holding out for clearer evidence that prescriptions continue rising beyond the year-end spike, when patient starts often fluctuate in rare cancers. Deals provide some support, but daily selling pressure ultimately hinges on U.S. demand.
However, a large portion of the Eisai payments are back-loaded. The larger milestone payments hinge on regulatory approvals and sales results in markets where Nuvation isn’t handling the launch, meaning timing could shift.
Nuvation started 216 new patients on IBTROZI in the fourth quarter, bringing total new patient starts since its mid-June launch to 432. It estimated fourth-quarter net product revenue at around $15.7 million. Cash and marketable securities stood at about $529.2 million as of Dec. 31. The company plans to release full fourth-quarter and full-year results in March. CEO David Hung is set to present at the J.P. Morgan Healthcare Conference on Tuesday, Jan. 13, at 6:45 p.m. ET.
